26 April 2018 2 Min Read
Bristol-Myers raises 2018 forecast, despite fewer sales of cancer drugs Sprycel and Yervoy
Sales of immuno-oncology medication Opdivo, by far the company’s most important growth driver, surged 34% to $1.51bn
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In